Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Observational study assessing demographic, economic and clinical factors associated with access and utilization of health care services of patients with multiple sclerosis under treatment with interferon beta-1b (EXTAVIA).
Hadjigeorgiou G, Dardiotis E, Tsivgoulis G, Doskas T, Petrou D, Makris N, Vlaikidis N, Thomaidis T, Kyritsis A, Fakas N, Treska X, Karageorgiou C, Sotirli S, Giannoulis C, Papadimitriou D, Mylonas I, Kouremenos E, Vlachos G, Georgiopoulos D, Mademtzoglou D, Vikelis M, Zintzaras E. Hadjigeorgiou G, et al. Among authors: fakas n. PLoS One. 2014 Nov 24;9(11):e113933. doi: 10.1371/journal.pone.0113933. eCollection 2014. PLoS One. 2014. PMID: 25419842 Free PMC article.
Correction: Observational study assessing demographic, economic and clinical factors associated with access and utilization of health care services of patients with multiple sclerosis under treatment with interferon beta-1b (EXTAVIA).
Hadjigeorgiou G, Dardiotis E, Tsivgoulis G, Doskas T, Petrou D, Makris N, Vlaikidis N, Thomaidis T, Kyritsis A, Fakas N, Treska X, Karageorgiou C, Sotirli S, Giannoulis C, Papadimitriou D, Mylonas I, Kouremenos E, Vlachos GS, Georgiopoulos D, Mademtzoglou D, Vikelis M, Zintzaras E. Hadjigeorgiou G, et al. Among authors: fakas n. PLoS One. 2015 Oct 6;10(10):e0140308. doi: 10.1371/journal.pone.0140308. eCollection 2015. PLoS One. 2015. PMID: 26440275 Free PMC article. No abstract available.
Consensus of the Hellenic Headache Society on the diagnosis and treatment of migraine.
Kouremenos E, Arvaniti C, Constantinidis TS, Giannouli E, Fakas N, Kalamatas T, Kararizou E, Naoumis D, Mitsikostas DD; Hellenic Headache Society. Kouremenos E, et al. Among authors: fakas n. J Headache Pain. 2019 Dec 13;20(1):113. doi: 10.1186/s10194-019-1060-6. J Headache Pain. 2019. PMID: 31835997 Free PMC article.
A Prospective, Observational, Cohort Study to Assess the Efficacy and Safety of Prolonged-Release Fampridine in Cognition, Fatigue, Depression, and Quality of Life in Multiple Sclerosis Patients: The FAMILY Study.
Mitsikostas DD, Doskas T, Gkatzonis S, Fakas N, Maltezou M, Papadopoulos D, Gourgioti R, Mitsias P. Mitsikostas DD, et al. Among authors: fakas n. Adv Ther. 2021 Mar;38(3):1536-1551. doi: 10.1007/s12325-020-01606-5. Epub 2021 Feb 2. Adv Ther. 2021. PMID: 33528792 Free PMC article.
Efficacy and Safety of Masitinib in Progressive Forms of Multiple Sclerosis: A Randomized, Phase 3, Clinical Trial.
Vermersch P, Brieva-Ruiz L, Fox RJ, Paul F, Ramio-Torrenta L, Schwab M, Moussy A, Mansfield C, Hermine O, Maciejowski M; AB07002 Study Group. Vermersch P, et al. Neurol Neuroimmunol Neuroinflamm. 2022 Feb 21;9(3):e1148. doi: 10.1212/NXI.0000000000001148. Print 2022 May. Neurol Neuroimmunol Neuroinflamm. 2022. PMID: 35190477 Free PMC article. Clinical Trial.
The prevalence and burden of medication overuse headache in Greece.
Constantinidis TS, Arvaniti C, Fakas N, Rudolf J, Kouremenos E, Giannouli E, Mitsikostas DD; Hellenic Headache Society. Constantinidis TS, et al. Among authors: fakas n. Cephalalgia. 2023 Jun;43(6):3331024231184909. doi: 10.1177/03331024231184909. Cephalalgia. 2023. PMID: 37377005 Free article.
Seasonal adherence to, and effectiveness of, subcutaneous interferon β-1a administered by RebiSmart® in patients with relapsing multiple sclerosis: results of the 1-year, observational GEPAT-SMART study.
Deftereos SN, Koutlas E, Koutsouraki E, Kyritsis A, Papathanassopoulos P, Fakas N, Tsimourtou V, Vlaikidis N, Tavernarakis A, Voumvourakis K, Arvanitis M, Sakellariou D, DeLorenzo F. Deftereos SN, et al. Among authors: fakas n. BMC Neurol. 2018 Nov 6;18(1):186. doi: 10.1186/s12883-018-1179-0. BMC Neurol. 2018. PMID: 30400884 Free PMC article.
Ofatumumab versus Teriflunomide in Multiple Sclerosis.
Hauser SL, Bar-Or A, Cohen JA, Comi G, Correale J, Coyle PK, Cross AH, de Seze J, Leppert D, Montalban X, Selmaj K, Wiendl H, Kerloeguen C, Willi R, Li B, Kakarieka A, Tomic D, Goodyear A, Pingili R, Häring DA, Ramanathan K, Merschhemke M, Kappos L; ASCLEPIOS I and ASCLEPIOS II Trial Groups. Hauser SL, et al. N Engl J Med. 2020 Aug 6;383(6):546-557. doi: 10.1056/NEJMoa1917246. N Engl J Med. 2020. PMID: 32757523 Clinical Trial.
21 results